Evommune is a clinical-stage biotechnology company developing small molecule and biologic therapies targeting chronic inflammatory diseases including chronic urticaria, atopic dermatitis, ulcerative colitis, and migraine. The company's lead program, EVO756, is an oral small molecule antagonist designed to modulate both mast cell activation and neuroinflammation, while EVO301 is a long-acting protein therapy that neutralizes pro-inflammatory IL-18 cytokine. Evommune generates revenue through sublicense agreements with Maruho for geographic rights to EVO756, upstream royalties owed to prior technology licensors, and potential development and sales milestone payments, while pursuing its own clinical development and commercialization strategy in large, underserved inflammatory disease markets.